Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Inv. presentation
Quarterly results
|
|
Furiex Pharmaceuticals, Inc. (FURX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/03/2014 |
8-K
| Form 8-K - Current report |
| 07/01/2014 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
| 05/28/2014 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/07/2014 |
8-K
| Quarterly results |
| 04/28/2014 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Agreement and Plan of Merger, by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc",
"Form of Contingent Value Rights Agreement by and between Forest Laboratories, Inc., and the Rights Agent",
"Stockholder Voting Agreement, by and between Forest Laboratories, Inc. and Fredric N. Eshelman, Pharm.D. and certain affiliates of Dr. Eshelman",
"Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology Deal Also Includes Up to $30 per share in a Contingent Value Right for Furiex Shareholders Creates a Leading GI Company within Forest - Acquisition Adds Global Rights to Eluxadoline - New Drug Application Expected to be Filed in 2014 - Eluxadoline is Complementary to Linzess for IBS-C and CIC and Additive to Forest's GI Treatments Acquired in Acquisition of Aptalis Forest to Partner with Royalty Pharma by Divesting Furiex's Royalty" |
|
| 03/11/2014 |
8-K
| Quarterly results |
| 02/04/2014 |
8-K
| Other Events, Financial Statements and Exhibits |
| 12/06/2013 |
8-K/A
| Financial Statements and Exhibits |
| 11/05/2013 |
8-K
| Quarterly results |
| 11/01/2013 |
8-K
| Form 8-K - Current report |
| 10/04/2013 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Second Amended and Restated Loan and Security Agreement dated September 30, 2013, by and among MidCap Funding III, LLC, Furiex Pharmaceuticals, Inc., APBI Holdings, LLC, Development Partners, LLC, GenuPro, Inc., and the lenders named therein",
"Second Omnibus Amendment and Reaffirmation Agreement dated September 30, 2013, by and among MidCap Funding III, LLC, LLC, Furiex Pharmaceuticals, Inc., APBI Holdings, LLC, Development Partners, LLC, and GenuPro, Inc",
"Subordination and Intercreditor Agreement dated September 30, 2013, by and among the Fredric Neville Eshelman Revocable Trust u/a dated July 13, 1988, as amended and/or restated, Furiex Pharmaceuticals, Inc., APBI Holdings, LLC, Development Partners, LLC, GenuPro, Inc., and MidCap Funding III, LLC",
"Loan and Security Agreement dated September 30, 2013, by and among the Fredric Neville Eshelman Revocable Trust u/a dated July 13, 1988, as amended and/or restated, Furiex Pharmaceuticals, Inc., APBI Holdings, LLC, Development Partners, LLC, and GenuPro, Inc",
"Secured Promissory Note dated September 30, 2013, to the Fredric Neville Eshelman Revocable Trust u/a dated July 13, 1988, as amended and/or restated",
"Pledge Agreement dated September 30, 2013, to Frederic Neville Eshelman, Trustee of the Fredric Neville Eshelman Revocable Trust u/a dated July 13, 1988, as amended and/or restated",
"Furiex Pharmaceuticals Enters into a Loan Agreement for $15 Million and Restructures its Existing Secured Loan" |
|
| 08/06/2013 |
8-K
| Quarterly results |
| 05/29/2013 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 03/06/2013 |
8-K
| Quarterly results |
| 11/01/2012 |
8-K
| Quarterly results |
| 08/08/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/02/2012 |
8-K
| Quarterly results |
| 07/30/2012 |
8-K
| Form 8-K - Current report |
| 05/25/2012 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/15/2012 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 05/03/2012 |
8-K
| Quarterly results |
| 02/21/2012 |
8-K
| Form 8-K - Current report |
| 12/13/2011 |
8-K
| Form 8-K - Current report |
| 11/18/2011 |
8-K
| Form 8-K - Current report |
| 11/01/2011 |
8-K
| Form 8-K - Current report |
| 09/07/2011 |
8-K
| Form 8-K - Current report |
| 08/24/2011 |
8-K
| Form 8-K - Current report |
| 05/24/2011 |
8-K
| Form 8-K - Current report |
| 04/28/2011 |
8-K
| Form 8-K - Current report |
| 02/22/2011 |
8-K
| Form 8-K - Current report |
| 12/10/2010 |
8-K
| Form 8-K - Current report |
| 09/13/2010 |
8-K
| Form 8-K - Current report |
| 08/11/2010 |
8-K
| Quarterly results |
| 06/18/2010 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Separation and Distribution Agreement, by and between Furiex Pharmaceuticals, Inc. and Pharmaceutical Product Development, Inc",
"Sublease Agreement, by and between Furiex Pharmaceuticals, Inc. and PPD Development, LP",
"Tax Sharing Agreement, by and between Furiex Pharmaceuticals, Inc. and Pharmaceutical Product Development, Inc",
"Employee Matters Agreement, by and between Furiex Pharmaceuticals, Inc. and Pharmaceutical Product Development, Inc",
"Transition Services Agreement, by and between Furiex Pharmaceuticals, Inc. and Pharmaceutical Product Development, Inc",
"Master Development Services Agreement, by and between Furiex Pharmaceuticals, Inc. and PPD Development, LP",
"Consulting Agreement, by and between Elk Mountain Consulting, LLC and Furiex Pharmaceuticals, Inc",
"PPD and Furiex Announce Completion of Spin-off" |
|
|
|
|